Publication: Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management
0
0
Issued Date
2024-01-01
Resource Type
eISSN
19485182
Scopus ID
2-s2.0-85191833637
Journal Title
World Journal of Hepatology
Volume
16
Issue
4
Start Page
550
End Page
565
Rights Holder(s)
SCOPUS
Bibliographic Citation
World Journal of Hepatology Vol.16 No.4 (2024) , 550-565
Suggested Citation
Leowattana W., Leowattana P., Leowattana T. Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management. World Journal of Hepatology Vol.16 No.4 (2024) , 550-565. 565. doi:10.4254/wjh.v16.i4.550 Retrieved from: https://hdl.handle.net/20.500.14740/20805
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
The management of hepatitis B virus (HBV) infection now involves regular and appropriate monitoring of viral activity, disease progression, and treatment response. Traditional HBV infection biomarkers are limited in their ability to predict clinical outcomes or therapeutic effectiveness. Quantitation of HBV core antibodies (qAnti-HBc) is a novel non-invasive biomarker that may help with a variety of diagnostic issues. It was shown to correlate strongly with infection stages, hepatic inflammation and fibrosis, chronic infection exacerbations, and the presence of occult infection. Furthermore, qAnti-HBc levels were shown to be predictive of spontaneous or treatment-induced HBeAg and HBsAg seroclearance, relapse after medication termination, re-infection following liver transplantation, and viral reactivation in the presence of immunosuppression. qAnti-HBc, on the other hand, cannot be relied on as a single diagnostic test to address all problems, and its diagnostic and prognostic potential may be greatly increased when paired with qHBsAg. Commercial qAnti-HBc diagnostic kits are currently not widely available. Because many methodologies are only semi-quantitative, comparing data from various studies and defining universal cut-off values remains difficult. This review focuses on the clinical utility of qAnti-HBc and qHBsAg in chronic hepatitis B management.